| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| sb 235699 | stress-activated protein kinase 2b | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Psoriasis[MeSHID:D011565] |
NA | discontinued in phase 1 | unknown |
| sb 235699 | map kinase p38 | NA | Successful target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Psoriasis[MeSHID:D011565] |
NA | discontinued in phase 1 | unknown |
| sb 235699 | stress-activated protein kinase 2a | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Psoriasis[MeSHID:D011565] |
NA | discontinued in phase 1 | unknown |
| click here to return to the previous page | ||||||||